<DOC>
	<DOCNO>NCT00000664</DOCNO>
	<brief_summary>To determine safety polyethylene glycolated IL-2 ( PEG IL2 ) administer weekly biweekly ( per amendment ) set oral zidovudine ( AZT ) . To determine effect PEG IL2 combination AZT parameter assess immune system well HIV virus antibody titer . To evaluate chronic dosing study phase offer patient complete initial 25-week regimen . Recent research focus enhance cell-mediated immunity reduce eliminate viral replication ( reproduction growth ) . A main thrust current treatment combination antiviral drug may effective combined use alone .</brief_summary>
	<brief_title>Safety Efficacy Polyethylene Glycolated IL-2 ( PEG IL-2 ) Plus Zidovudine HIV Positive , Asymptomatic Symptomatic Individuals</brief_title>
	<detailed_description>Recent research focus enhance cell-mediated immunity reduce eliminate viral replication ( reproduction growth ) . A main thrust current treatment combination antiviral drug may effective combined use alone . Four group studied period least 25 week . Patients observe minimum 6 hour infusion PEG IL2 . The 4 group patient : Group A - asymptomatic T4 count &gt; 400 cells/mm3 ( 7 patient ) ; Group B - asymptomatic T4 count 200 400 cells/mm3 ( 7 patient ) ; Group C - asymptomatic T4 count &lt; 200 cells/mm3 ( 5 patient ) ; Group D - diagnose AIDS relate complex ( ARC ) AIDS ( 7 patient ) . All patient receive AZT . After minimum 2-week period AZT , patient receive infusion PEG IL-2 3 consecutive weekly interval , follow 3-week period AZT alone . This cycle ( 3 week AZT PEG IL-2 follow 3 week AZT alone ) repeat total three time ( total 18 week ) follow 8 week AZT alone . PER AMENDMENT : Ten patient may qualify one two group : Group 1 - T4 count 200 - 400 cells/mm3 meet criterion establish Group B original protocol ; Group 2 - T4 count &lt; 200 cells/mm3 meet criterion establish Groups C D original protocol . Patients receive amend schedule PEG IL2 IV every week eight dos , dose escalation every week eight week permit Group 2 patient fail show 20 percent rise T4 count week 9 suffer CNS adverse event low dose . PER ADDITIONAL AMENDMENT : Up 10 additional patient may treat dose PEG IL2 biweekly schedule . Patients respond treatment biweekly schedule eligible additional 9 week current dose .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Prophylactic pentamidine Pneumocystis carinii pneumonia ( PCP ) . Topical steroid . Patients must : Be HIV positive . Fit one zidovudine use group list Disease Status . Be able give inform consent . Allowed : Basal cell carcinoma skin , situ carcinoma cervix , Kaposi 's sarcoma . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Major organ allograft . Significant cardiac disease central nervous system lesion . Known previous intolerance zidovudine ( AZT ) 500 mg/day . Active opportunistic infection . Score &gt; 0.5 ACTG AIDS dementia complex stag test . Any focal abnormality neurologic exam . Concurrent Medication : Excluded : Chemotherapy , hormonal therapy , immunotherapy . Other investigational drug , agent , device . Betablockers . Steroids topical . Antihypertensive medication diuretic . Concurrent Treatment : Excluded : Radiation therapy . Patients follow excluded : History seizure . Concurrent neoplasm specifically allow . Concomitant condition list Exclusion Coexisting Conditions . Prior Medication : Excluded within 30 day prior study entry : AntiHIV medication zidovudine ( AZT ) . Immunomodulators . Systemic steroid . Interferons . Interleukins . Other chemotherapy . Prior Treatment : Excluded within 30 day prior study entry : Radiation therapy . Excluded within 4 week prior study entry : Groups B , C , D Transfusions . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1994</verification_date>
	<keyword>Polyethylene Glycols</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Zidovudine</keyword>
</DOC>